These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38954031)

  • 21. Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.
    Yan Z; Huang L; Zhang X; Yu X; Huang R
    Sci Rep; 2024 Aug; 14(1):18444. PubMed ID: 39117725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
    Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
    Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
    Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
    Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
    Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
    Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
    Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.